PSA Billing Guidelines Updated November 2023



Key Changes at a Glance - Effective November 1, 2023

- 1.Introduction of a new PSA item for patients with a Significant Family History* New: Eligible for one PSA test every year
- 2.Change in testing frequency for patients <u>without</u> Significant Family History or Previous Prostatic Disease

New: One PSA test every 2 years (previously one PSA test every year)

3.Free-to-Total PSA Ratio

New: Implement clinical decision limits of total PSA > 3ug/L for men aged 50 – 69 to determine the need for additional PSA testing. For men with a significant family history, a lower threshold of >2 ug/L is used.

4. Previously Diagnosed Prostatic Disease

New: Medicare now accepts monitoring of prostatic malignancy and prostatitis only. It no longer accepts benign prostatic hypertrophy as "previous prostatic disease".

*Significant family history¹: Men whose risk of prostate cancer is estimated to be at least 2 times higher than the average, i.e., those with a father, brother, or son diagnosed with prostate cancer.

HOW TO ORDER PSA

To order, request "**PSA**" on our request form and include all relevant clinical and family history. Free-to-Total PSA ratio will be reported in accordance with Medicare billing criteria. **Note:** If free PSA is requested for patients who do not meet the Medicare criteria for payment, there may be an associated out-of-pocket fee.

CLINICAL NOTES

Written clinical notes on the request form advising prostatic disease are required. We are using the table below as valid clinical notes. Any other terminology is not considered valid.

Cancer of the prostate

Prostatic/Prostate adenocarcinoma

Prostatitis

Significant family history i.e., a first-degree relative (father, brother, or son) diagnosed with prostate cancer

PATIENT LAST NAME	GIVEN NAMES	NATA HEIMIKAL	Accrediad for compliance with PAAC Standards find ISO 15189 Accreditation Number: 2184	MEDICAI	RE CARD	NUMBER		PA R
PATIENT ADDRESS	2.1.640/23					SEX	DATE OF BIRTH	FIL
TESTS REQUESTED				PC	STCODE	TEL (HOME	E & MOBILE)	TEL
PSA								
CLINICAL NOTES Cancer of the prostate								
SELF DETERMINED	ENTIAL 🗖 CUMULATIVE							
QML Fee S.F. B.B. or D.B. VET AFFAIRS No:	IY TIME:		DO	CTOR'S SIG	NATURE A	ND REQUES	ST DATE	7
OPY REPORTS TO:			REQUEN					
ISPITAL/WARD			newDes)	ING DOCTOR	(PROVIDER	NUMBER, SURI	NAME, INITIALS, ADDRU	ESS) Di Cc Cc
a or will be patient be, at the time of the service of an experiment is dottance (r, depropriate point) a private patient to aprivate hospital a private patient to aprivate hospital private patient is anticopatient dospital private patient are acceptated hospital or adjustment of a recognized hospital or adjustment of	CARE ASSIGNMENT In 20A of the Health Insurance Act is ssign my right to benefits to the approved path rethough admirtuelities entropic that oligisat admirtuelities entropic that	PATIEN1 (973) Clogy X		URE AND I	DATE		PERSON DRAWING I	Col Hos
Collect Date Coll. Time Test Codes		Is recessary Init my Prac my claim Prac my claim Use Branch	fitioner's o Only Ref. No.	(Reason p	ationt cannot si	/	drawn from the patient na this patient by direct inquis immediately upon the bloc Signature:	vomen(s) ac kmed above iry and/or ins od being drau
		B/C	Clinic				Description & Containe	rs
APR No. 1 Pathology 11 Riverview Piece, Me T: 07) 3121 44 LAST NAME GIVEN NAMES	gy Pty Ltd (ABN 84 007 190 043) 300042 tra OML Pathology. troplex on Gateway, Murarine Cid 4 44 (24hr services) qml.com.au	172. Ternesi	RCPA	NATA TECHNICAL	Accredited for compliance with NNAC Standards and ISO 15189 Accredition Number: 2184	ME	DICARE CARD NUI	WBER
ADDRESS				SE		DATE OF B	IRTH FILE No.	
QUESTED			POST	CODE	TEL (HOME)	MOBILE)	TEL (BUS)	
PATIENT COL							Learn abou	

qml.com.au

Medicare Item Numbers

>

Medicare Prostate-Specific Antigen (PSA) billing criteria have been amended to align with NHMRC-endorsed guidelines². These changes consider family history, personal history of prostatic disease and previous or current PSA levels.

It is now crucial to provide relevant clinical notes when ordering a PSA test to ensure that patients do not receive unexpected out-of-pocket bills.

Healthcare providers should document patient's family history of prostatic cancer and personal history of prostatic diseases (if any) on the request form.

This information will be used to determine the appropriate billing and testing schedule for each patient. These criteria apply to requests for PSA testing from general practitioners, urologists and other medical specialists.

Prostate Specific Antigen (PSA): Total

Medicare Eligibility Criteria	Item Number	Testing Frequency
PSA Testing for those without significant family history or previously diagnosed prostatic disease	Item 66655	One PSA test every 2 years
PSA Testing for those with significant family history	Item 66654	One PSA test every year
PSA Testing for monitoring of previously diagnosed prostatic disease**	Item 66656	Unrestricted, as needed for monitoring

**Previously diagnosed prostatic disease includes prostate cancer, prostatitis and premalignant conditions such as atypical small acinar proliferation. Medicare no longer accepts monitoring of benign prostatic hypertrophy. Elevated PSA levels (above the method specific 97.5th age related upper reference limit) can be monitored using this item. (New.PN.14.2).

Prostate Specific Antigen(PSA): Free-to-Total Ratio

Medicare Eligibility Criteria	Item Number	Testing Frequency	
Follow-up of a patient without previously diagnosed prostatic disease and previous PSA result lies: - above 2.0 ug/L but below 5.6 ug/L for patients with family history; or - above 3.0 ug/L but below 5.6 ug/L for patients at or over 50 years of	Item 66659	One Test of free/total PSA ratio every year	
age but under 70 years of age; or - above 5.5 ug/L but below 10.0 ug/L for patients at or over 70 years of age.			
Monitoring of previously diagnosed prostatic disease when current PSA level lies:	Item 66660	Four Tests of free/total PSA ratio every year	
- above 2.0 ug/L but below 5.6 ug/L for patients with family history; or			
 above 3.0 ug/L but below 5.6 ug/L for patients at or over 50 years of age but under 70 years of age; or 			
- above 5.5 ug/L but below 10.0 ug/L for men at or over 70 years of age.			

References

1: PSA-Test-Reporting.aspx (rcpa.edu.au)

https://www.rcpa.edu.au/getattachment/75ca004c-4bc3-4104-8e1c-7e6a37f4ce15/PSA-Test-Reporting.aspx

2: PSA-Testing-Guidelines.pdf (pcfa.org.au) https://www.pcfa.org.au/media/612113/PSA-Testing-Guidelines.pdf

l!l laver

pathology

Healius companies

Hami

pathology

pathology

diagnostic pathology

